B · Normal
November 4th, Novo Nordisk expects the adjusted sales growth rate at constant exchange rates for the full year to be -2% to +2%, with an expected -2.35%.
Related telegraphs
November 4th, Novo Nordisk expects Wegovy oral medicine to be launched in more t
11-04 14:48
On November 4th, Novo Nordisk’s adjusted sales of Wegovy oral drug in the third
11-04 14:34
On October 20, Novo Nordisk said that its new generation weight loss drug CagriS
10-20 21:58
On October 7, the U.S. healthcare sector bucked the trend and rose early in the
10-07 21:52
[Nanexa and Novo Nordisk reach a 1.165 billion euro global licensing and coopera
09-25 13:33
September 23rd, Novo Nordisk is reported to be considering upgrading its New Yor
09-23 12:03
Comments